Clinical Trials Logo

Clinical Trial Summary

Silicosis is well-known occupational disease caused by free crystalline silica (silicon dioxide) and is marked by inflammation and pulmonary fibrosis. There are cumulative evidences that exposure to Caesar stone (quartz surface products that manufactured from up to 93% quartz, polymer resins and pigments) is particularly dangerous to exposed workers.

Goals: To examine marble workers exposed to Caesar Stone in order to propose a working plan of surveillance and prevention by biological monitoring.


Clinical Trial Description

Study participants would be recruited during two years of the study. They will be asked to come to a single visit at Pulmonary Laboratory of Tel Aviv Medical Center. During the meeting, participants will be given a precise explanation about the tests they will perform and after signing the informed consent will perform following tests:

1. Induced sputum (IS) - will be done after pretreatment with short acting beta-2 agonist and 3% saline will be administrated by an ultrasonic nebulizer for up to 20 min. Differential cell count, particle size distribution test of the particulate matter (with a Eyetech Analyzer (Ankersmid, Yokneam, Israel)will be done from IS samples and evaluation the activity of Heme oxygenase 1 (HO-1) protein from IS supernatants.

2. EBC-Exhaled Breath Condensate-will be done by condensation expiratory air and particulate matter and markers of oxidation will be measured.

3. Participants will be asked to complete occupational questionnaire.

4. Pulmonary function tests (PFTs): The measurement will be performed using standard protocols according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Including Lung diffusion testing.

Laboratory tests of induced sputum and EBC will be done within a week of a participant visit. Analysis of data will be done after the completion of data collection and laboratory tests. ;


Study Design

Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01338064
Study type Observational
Source Tel-Aviv Sourasky Medical Center
Contact Daria Bliznuk, BSc
Phone 972-0506353669
Email dasha_bl@yahoo.com
Status Not yet recruiting
Phase N/A
Start date September 2011
Completion date September 2013

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01329003 - DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone) N/A
Recruiting NCT04161014 - The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial Phase 2
Recruiting NCT05118256 - Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis Phase 2
Completed NCT02430259 - Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention Phase 3
Recruiting NCT06403800 - Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
Not yet recruiting NCT06011785 - Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil Early Phase 1
Not yet recruiting NCT05402176 - The SHIELD Whole Lung Lavage Study
Completed NCT02794701 - Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
Completed NCT01977131 - Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis Phase 1/Phase 2
Completed NCT00005280 - Specialized Center of Research in Occupational and Immunologic Lung Disease N/A
Recruiting NCT05538299 - Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
Completed NCT01725971 - Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis N/A
Recruiting NCT06090370 - Reducing Silica Exposure Among Brick Kiln Workers in Nepal N/A
Completed NCT04205708 - Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma
Recruiting NCT05546944 - The SHIELD Study-silicosis